![](/img/cover-not-exists.png)
PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE
Buehler, A., Kim, H.S.J., Fahham, L., Dionne, P.A., Castilho, G.Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.356
Date:
November, 2019
File:
PDF, 593 KB
2019